These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25271887)

  • 21. Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids.
    Goemans N; Tulinius M; Kroksmark AK; Wilson R; van den Hauwe M; Campion G
    Neuromuscul Disord; 2017 Mar; 27(3):203-213. PubMed ID: 28169120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ambulatory capacity in Japanese patients with Duchenne muscular dystrophy.
    Awano H; Itoh C; Takeshima Y; Lee T; Matsumoto M; Kida A; Kaise T; Suzuki T; Matsuo M
    Brain Dev; 2018 Jun; 40(6):465-472. PubMed ID: 29551259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reliability and validity analyses of the North Star Ambulatory Assessment in Brazilian Portuguese.
    Okama LO; Zampieri LM; Ramos CL; Toledo FO; Alves CRJ; Mattiello-Sverzut AC; Mayhew A; Sobreira CFR
    Neuromuscul Disord; 2017 Aug; 27(8):723-729. PubMed ID: 28648683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy.
    Kempen JC; Harlaar J; van der Kooi AJ; de Groot IJ; van den Bergen JC; Niks EH; Verschuuren JJ; Brehm MA
    Neuromuscul Disord; 2014 Mar; 24(3):216-21. PubMed ID: 24365209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Composite biomarkers for assessing Duchenne muscular dystrophy: an initial assessment.
    Shklyar I; Pasternak A; Kapur K; Darras BT; Rutkove SB
    Pediatr Neurol; 2015 Feb; 52(2):202-5. PubMed ID: 25447928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease.
    Kennedy RA; Carroll K; McGinley JL; Paterson KL
    J Foot Ankle Res; 2020 Mar; 13(1):10. PubMed ID: 32122377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal natural history in young boys with Duchenne muscular dystrophy.
    Coratti G; Brogna C; Norcia G; Ricotti V; Abbott L; D'Amico A; Berardinelli A; Vita GL; Lucibello S; Messina S; Sansone V; Albamonte E; Colia G; Salmin F; Gardani A; Manzur A; Main M; Baranello G; Arnoldi MT; Parsons J; Carry T; Connolly AM; Bertini E; Muntoni F; Pane M; Mercuri E
    Neuromuscul Disord; 2019 Nov; 29(11):857-862. PubMed ID: 31629611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures.
    Lerario A; Bonfiglio S; Sormani M; Tettamanti A; Marktel S; Napolitano S; Previtali S; Scarlato M; Natali-Sora M; Mercuri E; Bresolin N; Mongini T; Comi G; Gatti R; Ciceri F; Cossu G; Torrente Y
    BMC Neurol; 2012 Sep; 12():91. PubMed ID: 22974002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years.
    Goemans N; Klingels K; van den Hauwe M; Boons S; Verstraete L; Peeters C; Feys H; Buyse G
    PLoS One; 2013; 8(12):e84120. PubMed ID: 24391899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroids for the treatment of Duchenne muscular dystrophy.
    Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.
    Goemans N; Vanden Hauwe M; Signorovitch J; Swallow E; Song J;
    PLoS One; 2016; 11(10):e0164684. PubMed ID: 27737016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative electromyography in ambulatory boys with Duchenne muscular dystrophy.
    Verma S; Lin J; Travers C; McCracken C; Shah D
    Muscle Nerve; 2017 Dec; 56(6):1168-1171. PubMed ID: 28457006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
    Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
    PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
    McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
    Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cessation of ambulation results in a dramatic loss of trabecular bone density in boys with Duchenne muscular dystrophy (DMD).
    Crabtree NJ; Roper H; Shaw NJ
    Bone; 2022 Jan; 154():116248. PubMed ID: 34718220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes.
    Pane M; Mazzone ES; Sormani MP; Messina S; Vita GL; Fanelli L; Berardinelli A; Torrente Y; D'Amico A; Lanzillotta V; Viggiano E; D'Ambrosio P; Cavallaro F; Frosini S; Bello L; Bonfiglio S; Scalise R; De Sanctis R; Rolle E; Bianco F; Van der Haawue M; Magri F; Palermo C; Rossi F; Donati MA; Alfonsi C; Sacchini M; Arnoldi MT; Baranello G; Mongini T; Pini A; Battini R; Pegoraro E; Previtali SC; Napolitano S; Bruno C; Politano L; Comi GP; Bertini E; Morandi L; Gualandi F; Ferlini A; Goemans N; Mercuri E
    PLoS One; 2014; 9(1):e83400. PubMed ID: 24421885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of AFO use on walking in boys with Duchenne muscular dystrophy: a pilot study.
    Townsend EL; Tamhane H; Gross KD
    Pediatr Phys Ther; 2015; 27(1):24-9. PubMed ID: 25401456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.